Twenty-five percent is the royalty entitlement on U.S. Apitox economic proceeds that Apimeds Pharmaceuticals US, Inc. (APUS) has now pulled onto its own books, matching the 25% revenue participation right it simultaneously acquired on net proceeds from overseas rights agreements. Together with a 100% stake in Apitox rights for Korean medicine clinics in the Republic of Korea, those streams form the complete block of Assigned Rights that FreeT Inc. irrevocably transferred to Apimeds on August 19, 2026, under an Assignment and Transfer Agreement filed that day with the SEC.
What transferred, and what stayed out
The rights originated under a June 16, 2015 Apitox Rights Transfer Agreement, originally held by CNP Roen Co., Ltd., a Korean entity that subsequently changed its name to Inscobee Co., Ltd. and now operates as FreeT Inc. Apimeds confirmed the Assigned Rights are free and clear of any claims or encumbrances, including obligations tied to prior side-letter arrangements with Lokahi Therapeutics Inc.
The carve-outs are explicit. Global rights FreeT did not itself hold stay out. Underlying intellectual property ownership in Apitox stays out. Rights specific to indications, territories, manufacturing, regulatory processes, or commercialization activities not originally granted to FreeT also fall outside the transfer. Apimeds assumes only obligations arising after the August 19 effective date and directly related to exercising the Assigned Rights; no pre-effective-date liabilities of FreeT under the 2015 agreement pass to Apimeds.
The package also carries quarterly reporting rights. Apimeds is now entitled to receive quarterly updates on the Apitox clinical program's status and on overseas rights transactions, plus certain data and technology benefits tied to third-party manufacturing or rights agreements.
FreeT's forward commitment
FreeT confirmed its intention to support continued Apitox development and global commercialization through Apimeds. The Korean company stated it would use commercially reasonable efforts to facilitate future transactions that could bring additional Apitox rights for territories outside the United States to Apimeds. Each future territory requires its own separate definitive agreement.
The Assignment Agreement is governed by Korean law, with exclusive jurisdiction in the Seoul Central District Court. Chief Executive Officer Dr. Vin Menon signed the 8-K on behalf of Apimeds, which is headquartered at 100 Matawan Road, Suite 325, Matawan, New Jersey, and trades on NYSE American under the ticker APUS.
Related reading
- Niki BioSolutions H1 2026: net loss triples to $1.31M as R&D spending surges from $19K to $384K
- FFAI amendment splits fourth closing, strips warrant obligations from $41 million capital structure
- Johnson & Johnson leads Abbott Laboratories in Dividend King matchup on valuation and streak
- Khan's 43 abandoned mergers set the bar as Ferguson's FTC weighs Covetrus-MWI Animal Health deal